Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescript...
EXIBIT: Oxaliplatin in Biliary Tract Cancer
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 67
- Registration Number
- NCT00174564
MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 118
- Registration Number
- NCT00174798
- Locations
- 🇺🇸
Hudson Valley Urology Center, Kingston, New York, United States
🇺🇸Hudson Valley Urology, Poughkeepsie, New York, United States
🇺🇸Rockhill Medical Plaza, Kansas City, Missouri, United States
TRACE: Tirapazamine-Radiation And Cisplatin Evaluation
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 317
- Registration Number
- NCT00174837
- Locations
- 🇳🇿
sanofi-aventis New Zealand administrative office, Macquarie Park, New Zealand
🇨🇳Sanofi-Aventis Administrative Office, Taipei, Taiwan
CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1460
- Registration Number
- NCT00174759
- Locations
- 🇬🇧
Sanofi-Aventis, Guildford, United Kingdom
Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 390
- Registration Number
- NCT00174681
- Locations
- 🇸🇮
Sanofi-Aventis, Ljubljana, Slovenia
Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-12-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 232
- Registration Number
- NCT00174863
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guilford Surrey, United Kingdom
🇦🇺sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia
CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 87
- Registration Number
- NCT00174616
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2010-02-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 72
- Registration Number
- NCT00174772
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guilford, United Kingdom
A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 4628
- Registration Number
- NCT00174785
- Locations
- 🇩🇪
Sanofi-aventis Administrative Office, Berlin, Germany
🇬🇧Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
GILT Docetaxel - Non-Small Cell Lung Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 449
- Registration Number
- NCT00174629
- Locations
- 🇨🇭
Sanofi-Aventis, Genève, Switzerland